Aquestive Therapeutics (AQST) Free Cash Flow (2017 - 2026)

Aquestive Therapeutics' Free Cash Flow history runs 10 years deep, the most recent figure standing at -$14.9 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 36.87% year-over-year to -$14.9 million; the TTM figure through Mar 2026 stood at -$44.3 million (up 9.63% YoY), while the FY2025 annual figure was -$53.0 million, down 47.54% from the prior year.
• Free Cash Flow was -$14.9 million for Q1 2026 at Aquestive Therapeutics, down from -$8.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $8.8 million in Q1 2023 to a low of -$23.5 million in Q1 2025.
• Historically, Free Cash Flow has averaged -$7.2 million across 5 years, with a median of -$7.9 million in 2025.
• The sharpest annual moves came in 2022 and 2024: Free Cash Flow soared 197.63% in 2022, then plunged 381.35% in 2024.
• A 5-year view of Free Cash Flow shows it stood at $8.4 million in 2022, then sank by 159.09% to -$5.0 million in 2023, then tumbled by 31.18% to -$6.5 million in 2024, then plunged by 31.52% to -$8.6 million in 2025, then slumped by 73.7% to -$14.9 million in 2026.
• The last three Free Cash Flow figures came in at -$14.9 million (Q1 2026), -$8.6 million (Q4 2025), and -$13.0 million (Q3 2025), per Business Quant data.